Green Cross Medical Science Corporation (142280) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has a cash flow conversion efficiency ratio of -0.013x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-714.99 Million ≈ $-484.54K USD) by net assets (₩56.08 Billion ≈ $38.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 142280 market cap overview for the company's overall valuation and market capitalisation.
Green Cross Medical Science Corporation - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Green Cross Medical Science Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Green Cross Medical Science Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Green Cross Medical Science Corporation ranked by their cash flow conversion efficiency. Explore Green Cross Medical Science Corporation cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Energy Offshore Services AS
OL:GEOS
|
-0.117x |
|
Bluebird bio Inc
NASDAQ:BLUE
|
0.751x |
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Feytech Holdings Berhad
KLSE:5322
|
0.054x |
|
Cherrybro co.Ltd
KQ:066360
|
0.064x |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
-0.005x |
|
Indonesia Energy
NYSE MKT:INDO
|
-0.054x |
|
Digihost Technology Inc
V:DGHI
|
-0.819x |
Annual Cash Flow Conversion Efficiency for Green Cross Medical Science Corporation (2014–2025)
The table below shows the annual cash flow conversion efficiency of Green Cross Medical Science Corporation from 2014 to 2025. View latest Green Cross Medical Science Corporation stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩46.37 Billion ≈ $31.42 Million |
₩7.20 Billion ≈ $4.88 Million |
0.155x | +74.72% |
| 2024-12-31 | ₩41.21 Billion ≈ $27.93 Million |
₩3.66 Billion ≈ $2.48 Million |
0.089x | -22.67% |
| 2023-12-31 | ₩36.92 Billion ≈ $25.02 Million |
₩4.24 Billion ≈ $2.87 Million |
0.115x | -64.89% |
| 2022-12-31 | ₩33.25 Billion ≈ $22.54 Million |
₩10.88 Billion ≈ $7.37 Million |
0.327x | +164.94% |
| 2021-12-31 | ₩36.11 Billion ≈ $24.47 Million |
₩-18.20 Billion ≈ $-12.33 Million |
-0.504x | -224.76% |
| 2020-12-31 | ₩56.47 Billion ≈ $38.27 Million |
₩-8.76 Billion ≈ $-5.94 Million |
-0.155x | -87.24% |
| 2019-12-31 | ₩49.58 Billion ≈ $33.60 Million |
₩-4.11 Billion ≈ $-2.78 Million |
-0.083x | -146.02% |
| 2018-12-31 | ₩15.34 Billion ≈ $10.40 Million |
₩-516.61 Million ≈ $-350.10K |
-0.034x | -125.18% |
| 2017-12-31 | ₩23.23 Billion ≈ $15.75 Million |
₩3.11 Billion ≈ $2.11 Million |
0.134x | -64.95% |
| 2016-12-31 | ₩26.85 Billion ≈ $18.20 Million |
₩10.25 Billion ≈ $6.94 Million |
0.382x | +302.32% |
| 2015-12-31 | ₩28.87 Billion ≈ $19.56 Million |
₩-5.45 Billion ≈ $-3.69 Million |
-0.189x | -167.97% |
| 2014-12-31 | ₩31.50 Billion ≈ $21.35 Million |
₩-2.22 Billion ≈ $-1.50 Million |
-0.070x | -- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more